1. Scrip
  2. >>Business
  3. >>Strategy

Dermira Ends UCB Cimzia Psoriasis Pact To Focus On Its Own Pipeline

 
• By Sten Stovall

As it ends its pact with UCB, Dermira says it needs to focus on its own top assets and couldn't simultaneously launch Cimzia in psoriasis.

Skin condition
Demira Ends UCB Cimza Psoriasis Pact To Focus On Own Dermatology • Source: Shutterstock

Dermira Inc. is ending its partnership with UCB SA developing the Belgian company's biologic Cimzia (certolizumab pegol) in the US, EU and Canada for the treatment of psoriasis to fully focus on its own dermatological assets, two of which are in pivotal Phase III trials.

‍Dermira in-licensed Cimzia, a marketed rheumatoid arthritis drug, from UCB in 2014 which Dermira has been developing for plaque psoriasis,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

More from Business

Quick Listen: Scrip’s Five Must-Know Things

 
• By Ian Haydock

In this week's episode: Merck & Co’s Verona acquisition; venture funding plummets in Q2; how Teva is expanding innovation; Apogee’s Phase II eczema win; and a look at India’s wave of licensing.

Capricor Gets Complete Response For DMD Cell Therapy

 
• By Joseph Haas

Seven weeks before its action date, Capricor got an FDA complete response for cell therapy deramiocel in DMD-related cardiomyopathy. It has a Phase III study nearing readout, though.

Bayer Bags First Global Okay For Hot Flashes Therapy

 
• By Kevin Grogan

Lynkuet will compete with Astellas's Veozah/Veoza